Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKBA:
- Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Options Volatility and Implied Earnings Moves Today, August 25, 2023
- Notable companies reporting before tomorrow’s open
- Akebia expects to resubmit vadadustat NDA in Q3
- Akebia backs 2023 Auryxia net product revenue view of $175M-$180M